

**AMENDMENTS TO THE CLAIMS:**

Please cancel claims 1-10, 12-17 and 19 without prejudice.

Please add new claims 20-25.

Please amend claims 11 and 18 as follows:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-10 (Cancelled)

11. (Currently amended) A method of diagnosing ~~carcinoma~~ cancer comprising: a) ~~determining the expression of one or more genes comprising a nucleic acid sequence selected from the group consisting of the sequences outlined in Table 1, in~~ determining the level of an expression product comprising an nucleotide sequence having at least 95% sequence identity to SEQ ID NO:59, or a complement thereof, in a sample comprising a first tissue type of a first individual; and b) comparing said expression of said gene(s) from said levels of the expression product in (a) to:

(1) levels of the expression product in a second sample, said second sample comprising a second normal tissue type from said first individual, or (2) levels of the expression product in a third sample, said third sample comprising a normal tissue type from or a second unaffected individual; wherein a difference in said expression indicates an increase of at least 50% between the level of the expression products in (a) and the level of the expression products in the second sample or the third sample indicates that the first individual has ~~carcinoma~~ cancer.

Claims 12-17 (Cancelled)

18. (Currently amended) A method of diagnosing ~~carcinoma~~ cancer or a propensity to ~~carcinoma~~ cancer by sequencing at least one expression product comprising a nucleotide sequence having at least 95% sequence identity to SEQ ID NO: 59 ~~CA gene of~~ in an individual.

Claim 19 (Cancelled).

20. (New) The method of claim 11, wherein the nucleotide sequence has a sequence identity of at least about 98% with SEQ ID NO:59 or a complement thereof.
21. (New) The method of claim 11, wherein said nucleotide sequence comprises SEQ ID NO:59 or complement thereof.
22. (New) The method of claim 11 wherein the cancer is colon cancer, breast cancer, or prostate cancer.
23. (New) The method of claim 11 wherein the cancer is carcinoma.
24. (New) The method of claim 11, wherein the difference between the level of the expression products in (a) and the level of the expression products in the second or the third sample is at least 100%.
25. (New) The method of claim 11, wherein the difference between the level of the expression products in (a) and the level of the expression products in the second or the third sample is at least 150%.